Real-time enrollment status for this hereditary hemorrhagic telangiectasia clinical trial
Current Status
Recruiting
Checked: July 13, 2026 at 8:46 AM UTC
| NCT Number | NCT06659640 |
| Recruiting Status | Recruiting |
| Condition | Hereditary Hemorrhagic Telangiectasia |
| Phase | Clinical Trial |
| Target Enrollment | 120 participants |
| Active Locations | 8 sites in the US |
| Sponsor | Alnylam Pharmaceuticals |
| Last Updated on CT.gov | June 12, 2026 (Jun 12, 2026) |
As of July 13, 2026: Clinical trial NCT06659640 is currently recruiting participants. This clinical trial study for hereditary hemorrhagic telangiectasia is actively seeking new participants at 8 locations across the United States. The study is sponsored by Alnylam Pharmaceuticals. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT06659640 is actively recruiting participants as of July 13, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 8 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT06659640 was last updated Jun 12, 2026 (June 12, 2026). HelloStudys verifies this status automatically.